Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Viatris

Status: Completed

Conditions: Hypertension; Hypercholesterolemia; Angina Pectoris; Familial Hypercholesterolemia

Treatments: Drug: Amlodipine/Atorvastatin

Study type: Observational

Funder types: Industry

Identifiers

NCT01107743

A3841063

Details and patient eligibility

About

In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.

Full description

All the subjects whom an investigator prescribes the first Amlodipine /Atorvastatin (Caduet®) Combination Tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 1,291 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female subjects intend to treat their cardiovascular disease who are prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets by their Physicians

Exclusion criteria

Subjects who have been prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets before.

Trial design

1,291 participants in 1 patient group

Amlodipine and Atorvastatin Combination Tablet

Description:

Subjects taking Amlodipine and Atorvastatin Combination Tablets

Treatment:

Drug: Amlodipine/Atorvastatin